Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963533 | 1.00 | HTT (0.41) | HTTSMN1; SMN2MAPTNR2F2L3MBTL1 | |
| SCHEMBL966081 | 0.91 | CCNC (0.42) | HTTSMN1; SMN2MAPTNR2F2L3MBTL1 | |
| SCHEMBL962582 | 0.88 | SMN1; SMN2 (0.44) | HTTSMN1; SMN2MAPTNR2F2L3MBTL1 | |
| SCHEMBL962581 | 0.88 | SMN1; SMN2 (0.44) | HTTSMN1; SMN2MAPTNR2F2L3MBTL1 | |
| SCHEMBL962500 | 0.86 | L3MBTL1 (0.50) | HTTSMN1; SMN2MAPTNR2F2L3MBTL1 | |
| SCHEMBL962501 | 0.86 | L3MBTL1 (0.50) | HTTSMN1; SMN2MAPTNR2F2L3MBTL1 | |
| SCHEMBL966085 | 0.83 | SMN1; SMN2 (0.41) | HTTSMN1; SMN2MAPTNR2F2L3MBTL1 | |
| SCHEMBL27772576 | 0.83 | SMN1; SMN2 (0.41) | HTTSMN1; SMN2MAPTNR2F2L3MBTL1 | |
| SCHEMBL962725 | 0.82 | MAPT (0.35) | HTTSMN1; SMN2MAPTNR2F2L3MBTL1 | |
| SCHEMBL962726 | 0.82 | MAPT (0.35) | HTTSMN1; SMN2MAPTNR2F2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | HTT 3799/4885SMN1; SMN2 4710/4885MAPT 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.